Alamar Biosciences affiliate proposes $36.7M share sale

The notice names J.P. Morgan Securities LLC as broker and Nasdaq Stock Market as the exchange for the proposed sale.

Rhea-AI Filing Summary

Alamar Biosciences, Inc. (ALMR) is the issuer in a notice that Qiming Venture Partners VI, L.P., identified as an affiliate, proposes to sell 1,558,858 common shares. The notice lists an aggregate market value of $36,664,000.00, J.P. Morgan Securities LLC as broker, and Nasdaq Stock Market as the exchange. The approximate sale date is October 14, 2026; the notice lists 69,392,766 shares outstanding.

Key Figures

Proposed shares: 1,558,858 shares Aggregate market value: $36,664,000.00 Shares outstanding: 69,392,766 shares +1 more

4 metrics

Proposed shares 1,558,858 shares Proposed sale by Qiming Venture Partners VI, L.P.

Aggregate market value $36,664,000.00 Proposed sale

Shares outstanding 69,392,766 shares Issuer share count listed in the notice

Approximate sale date October 14, 2026 Proposed sale

Key Terms

Series A-3 preferred shares, Series A-4 preferred shares, Series B preferred

3 terms

Series A-3 preferred shares financial

"Private investment in Series A-3 preferred shares"

Series A-4 preferred shares financial

"Private investment in Series A-4 preferred shares"

Series B preferred financial

"Private investment in Series B preferred"

Series B preferred is a class of ownership created during a later private funding round that gives investors special rights ahead of ordinary shareholders. Think of it like a priority ticket at a crowded exit: holders get paid or reimbursed before common shareholders if the company is sold or winds down, often receive fixed payments or protection against value loss, and typically have options to convert into regular shares; those features affect potential returns and control for investors.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ALMR shares does Qiming Venture Partners VI, L.P. propose to sell?

Qiming Venture Partners VI, L.P. proposes to sell 1,558,858 Alamar common shares, with an aggregate market value of $36,664,000.00. The approximate sale date listed is October 14, 2026. The notice also lists 69,392,766 shares outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/14/2026 - 08:21 PM EDT Accepted by SEC EDGAR 10/14/2026 - 08:20 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001733278
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Alamar Biosciences, Inc.
SEC File Number	001-43235
Address of Issuer	47071 BAYSIDE PARKWAY FREMONT CALIFORNIA 94538
Phone	510-626-9888
Name of Person for Whose Account the Securities are To Be Sold	Qiming Venture Partners VI, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock, par value $0.0001 per share	J.P. Morgan Securities LLC 270 Park Avenue New York NY 10117	1558858	36664000.00	69392766	10/14/2026	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	05/27/2020	Private investment in Series A-3 preferred shares, automatically converted into common stock upon IPO	Issuer			2648607	05/26/2020	Check
Common stock	04/30/2021	Private investment in Series A-4 preferred shares, automatically converted into common stock upon IPO	Issuer			2373437	04/30/2021	Check
Common stock	08/20/2021	Private investment in Series B preferred, automatically converted into common stock upon IPO	Issuer			1859366	08/18/2021	Check

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	10/14/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Ho Man Lam
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)